<div><div></div><div><span><p><span>INSMED's Chair and CEO, William Lewis, sold a total of 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan. The transactions occurred at weighted average prices of $147.17, $148.02, and $148.83, resulting in a total sale amount of $1,979,763. Following these transactions, Lewis directly owns 301,185 shares and indirectly owns 284,424 shares of INSMED common stock through the Katie Procter Dynasty Trust and the William Lewis Family Legacy Trust.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Lewis William</span></td></tr><tr><td><span>Relationship</span></td><td><span>Chair and CEO</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$1,979,763</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>SEC Filing: </span>INSMED Inc [ INSM ] - Form 4 - Feb. 11, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

INSM

<p>INSMED's Chair and CEO, William Lewis, sold 13,396 shares of common stock on February 9, 2026, under a 10b5-1 trading plan, totaling $1,979,763. The shares were sold at average prices of $147.17, $148.02, and $148.83. Post-sale, Lewis holds 301,185 shares directly and 284,424 shares indirectly through trusts.</p>

TradingView

Invesco Biotechnology & Genome ETF

VG Health

Insmed

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Dorsey Wright Healthcare Momentum ETF

VanEck Biotech ETF

INSMED Chair and CEO William Lewis Sells 13,396 Shares